This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales
by Zacks Equity Research
BAYRY's fourth-quarter earnings match expectations. Revenues top estimates, driven by the strong performance of its pharmaceutical business.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Buy Johnson & Johnson (JNJ) Stock for Higher Highs?
by Shaun Pruitt
Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today
by Zacks Equity Research
Johnson & Johnson (JNJ) reachead $167.28 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
by Kanishka Das
NRXP is expected to provide updates on its pipeline candidates being developed for treating central nervous system disorders when it reports fourth-quarter earnings release.
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
by Zacks Equity Research
The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
5 Stocks in the Dow ETF That Survived the Worst Week Since October
by Sweta Killa
Dow Jones witnesses its biggest weekly drop since October amid renewed concerns about economic growth. Let's look at the stocks that survived.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
by Zacks Equity Research
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close.
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
by Zacks Equity Research
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
by Ahan Chakraborty
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
ISRG Nears $600: Can the Stock Breach the Mark Again This Month?
by Indrajit Bandyopadhyay
Intuitive Surgical has maintained an uptrend in the past six months on the back of robust da Vinci portfolio performance. The stock has also gained during the past month. Let's see if the trend might change.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
by Kinjel Shah
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
ROKU Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
Roku's fourth-quarter 2024 results benefit from consistent growth in streaming households and streaming hours on The Roku Channel.
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.